| abstract |
The invention discloses the application of PEG10 gene/protein as a target in the preparation of anti-cutaneous T-cell lymphoma products. The nucleotide sequence of the PEG10 gene is from positions 94,656,370 to 94,665,698 of the genbank accession number ENST00000612748.1. The examples of the present invention show that inhibiting the expression of PEG10 gene in CTCL cells, the cells are significantly reduced, the tumor formation ability in vitro is weakened, and the growth of CTCL tumors in a xenograft mouse model is inhibited. |